Ryo Okuyama
Daiichi Sankyo
27 Papers
230 Citations
Ryo Okuyama is an academic researcher from Daiichi Sankyo. The author has contributed to research in topics: Derivative (chemistry) & Alkyl. The author has an hindex of 14, co-authored 27 publications. Previous affiliations of Ryo Okuyama include Amgen.
Chat about Author
Papers
Potent and Orally Bioavailable GPR142 Agonists as Novel Insulin Secretagogues for the Treatment of Type 2 Diabetes.
Narihiro Toda,Xiaolin Hao,Ogawa Yasuyuki,Kozo Oda,Ming Yu,Zice Fu,Yi Chen,Yong-Jae Kim,Mike Lizarzaburu,Sarah E. Lively,Shauna Lawlis,Michiko Murakoshi,Futoshi Nara,Nobuaki Watanabe,Jeff D. Reagan,Hui Tian,Angela Fu,Alykhan Motani,Qingxiang Liu,Yi-Jyun Lin,Run Zhuang,Yumei Xiong,Peter Fan,Julio C. Medina,Leping Li,Masanori Izumi,Ryo Okuyama,Satoshi Shibuya +27 more
TL;DR: The optimization of HTS hit compound 1 toward a proof of concept compound 33, which showed potent glucose lowering effects during an oral glucose tolerance test in mice and monkeys, is reported here.
45
Discovery and optimization of a novel series of GPR142 agonists for the treatment of type 2 diabetes mellitus.
Mike Lizarzaburu,Simon Turcotte,Xiaohui Du,Jason Duquette,Angela Fu,Jonathan B. Houze,Leping Li,Jinqian Liu,Michiko Murakoshi,Kozo Oda,Ryo Okuyama,Futoshi Nara,Jeff D. Reagan,Ming Yu,Julio C. Medina +14 more
TL;DR: The structure-activity-relationship around the major areas of the molecule was explored to give agonists 90 times more potent than the initial HTS hit in a human GPR142 inositol phosphate accumulation assay.
39
Identification of molecular target of AMP-activated protein kinase activator by affinity purification and mass spectrometry.
Toshiyuki Kosaka,Ryo Okuyama,Weiyong Sun,Tsuneaki Ogata,Jun Harada,Kazushi Araki,Masanori Izumi,Taishi Yoshida,Akira Okuno,Fujiwara Toshihiko,Jun Ohsumi,Kimihisa Ichikawa +11 more
TL;DR: The approach can provide crucial information about the molecular targets of small molecular compounds, especially target proteins not yet identified, as well as elucidate the mechanism of AMPK activation by D942.
35
Novel and potent inhibitors of stearoyl-CoA desaturase-1. Part II: Identification of 4-ethylamino-3-(2-hydroxyethoxy)-N-[5-(3-trifluoromethylbenzyl)thiazol-2-yl]benzamide and its biological evaluation.
Yoshikazu Uto,Tsuneaki Ogata,Yohei Kiyotsuka,Yuriko Miyazawa,Yuko Ueno,Hitoshi Kurata,Tsuneo Deguchi,Makiko Yamada,Nobuaki Watanabe,Toshiyuki Takagi,Satoko Wakimoto,Ryo Okuyama,Masahiro Konishi,Nobuya Kurikawa,Keita Kono,Jun Osumi +15 more
TL;DR: The continuing investigation of SAR studies of 3-(2-hydroxyethoxy)-N-(5-benzylthiazol-2-yl)-benzamides as stearoyl-CoA desaturase-1 (SCD-1) inhibitors is reported.
31
Novel benzoylpiperidine-based stearoyl-CoA desaturase-1 inhibitors: Identification of 6-[4-(2-methylbenzoyl)piperidin-1-yl]pyridazine-3-carboxylic acid (2-hydroxy-2-pyridin-3-ylethyl)amide and its plasma triglyceride-lowering effects in Zucker fatty rats.
Yoshikazu Uto,Tsuneaki Ogata,Yohei Kiyotsuka,Yuko Ueno,Yuriko Miyazawa,Hitoshi Kurata,Tsuneo Deguchi,Nobuaki Watanabe,Masahiro Konishi,Ryo Okuyama,Nobuya Kurikawa,Toshiyuki Takagi,Satoko Wakimoto,Jun Ohsumi +13 more
TL;DR: This compound exhibited good oral bioavailability and demonstrated plasma triglyceride lowering effects in Zucker fatty rats in a dose-dependent manner after a 7-day oral administration (qd).
30